Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31662030 | 0.87 | CNR1 (0.48) | HPGDSMN1; SMN2CNR1 | |
| SCHEMBL11002220 | 0.87 | SMN1; SMN2 (0.62) | HPGDSMN1; SMN2KMT2ACA1CA2 | |
| SCHEMBL17859718 | 0.87 | HPGD (0.58) | HPGDSMN1; SMN2KMT2ACA1CA2 | |
| SCHEMBL12974297 | 0.85 | KMT2A (0.48) | HPGDSMN1; SMN2KMT2AACHELMNA | |
| SCHEMBL8318576 | 0.84 | KMT2A (0.62) | HPGDSMN1; SMN2KMT2ALMNAPOLB | |
| SCHEMBL10642584 | 0.84 | KMT2A (0.58) | HPGDSMN1; SMN2KMT2ACA1CA2 | |
| SCHEMBL29194822 | 0.83 | CYP1A2 (0.59) | HPGDSMN1; SMN2KMT2ACA1CA2 | |
| SCHEMBL29194819 | 0.83 | CYP1A2 (0.59) | HPGDSMN1; SMN2KMT2ACA1CA2 | |
| SCHEMBL31500690 | 0.83 | HPGD (0.63) | HPGDSMN1; SMN2KMT2ACA1CA2 | |
| SCHEMBL31500691 | 0.83 | HPGD (0.63) | HPGDSMN1; SMN2KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962244-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | HPGD 4744/4885SMN1; SMN2 2721/4885KMT2A 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.